Skip to main content
Clinical Trials/CTRI/2023/08/056902
CTRI/2023/08/056902
Recruiting
Phase 3

Effect of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation and Brachytherapy in Cervix Cancer Stage IIIC1/IIIC2 - a Phase III Prospective Randomized Controlled Trial - ENACT-RT

Dr. Partha Sarathi Bhattacharyya0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified
Sponsor
Dr. Partha Sarathi Bhattacharyya
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Dr. Partha Sarathi Bhattacharyya

Eligibility Criteria

Inclusion Criteria

  • 1\. Cancer of the uterine cervix considered suitable for curative treatment with definitive radio\-(chemo)therapy including BT
  • 2\. Biopsy proven cervix cancer (squamous, adenocarcinoma, and adeno\-squamous histology) within the age group of 18 to 70 years.
  • 3\. Radiologically confirmed stage IIIC1 and IIIC2 (according to FIGO and TNM staging guidelines)
  • 4\. Eastern Cooperative oncology Group (ECOG) performance status \< 2
  • 5\. Adequate organ reserve
  • 6\. Willingness to include in the trial (informed consent form).

Exclusion Criteria

  • 1\. Patients with any other FIGO stage than IIIC1 and IIIC2
  • 2\. Small cell neuroendocrine cancer, melanoma and other rare cancers in the cervix
  • 3\. A proven history of previous malignancies / radiation
  • 5\. NYHA class III heart failure
  • 6\. CTCAE v5\.0 Grade \=2 peripheral neuropathy
  • 7\. Baseline hearing loss
  • 8\. HIV or Hepatitis B or Hepatitis C infection
  • 9\. Mental illness
  • 10\. Pregnant and lactating women

Outcomes

Primary Outcomes

Not specified

Similar Trials